Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
Clinical trial NCT05982834 · UNKNOWN
Trial details
- NCT number
- NCT05982834
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-09
- Primary completion
- 2025-05-01
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.